Daratumumab monotherapy in patients with heavily pretreated ...

First-line daratumumab shows high efficacy and tolerability even in ...

... monotherapy arm versus four ... Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis.

Daratumumab Combo Sparks 81% Response Rate in Myeloma

The addition of daratumumab to a standard multiple myeloma regimen generated responses in 81% of patients with relapsed or refractory ...

REAL-WORLD RESULTS OF DARATUMUMAB MONOTHERAPY IN ...

REAL-WORLD RESULTS OF DARATUMUMAB MONOTHERAPY IN HEAVILY PRETREATED RELAPSED/REFRACTORY MULTIPLE MYELOMA IN POLAND: A PROSPECTIVE OBSERVATIONAL STUDY OF THE ...

Impressive Results With Daratumumab Plus Lenalidomide ...

In relapsed/refractory patients, daratumumab plus lenalidomide (Revlimid)/dexamethasone yielded an 81% response rate, with durable remissions, ...

Saad Z. Usmani,1,* Hareth Nahi,2 Brendan M. Weiss,3 Nizar J ...

Safety and Efficacy of Daratumumab Monotherapy in Patients With Heavily Pretreated Relapsed and. Refractory Multiple Myeloma: Final Results ...

An overview of daratumumab monotherapy for heavily treated ...

... daratumumab, as a novel, well-tolerated, single-agent therapy for patients with heavily treated multiple myeloma.

Daratumumab Approved by FDA for Pretreated Multiple Myeloma

The FDA has given accelerated approval to the CD38-targeted monoclonal antibody daratumumab as a monotherapy for patients with multiple ...

Daratumumab in the treatment of heavily pretreated ... - YouTube

The study included heavily pretreated patients who were refractory to therapies such as rituximab. Daratumumab ... The study included heavily ...

Clinical efficacy of daratumumab monotherapy in patients with ...

Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma ... Key Points A pooled analysis of 2 ...

Economic Evaluation of Adding Daratumumab to Carfilzomib and ...

... daratumumab monotherapy for patients ... patients with heavily pretreated relapsed-refractory multiple myeloma in the United States.

talquetamab + daratumumab in R/R multiple myeloma - VJHemOnc

The study included heavily pretreated patients, including many that had received prior BCMA-directed therapy. The study's results indicated a ...

Final analysis of CENTAURUS: daratumumab monotherapy for SMM

... daratumumab monotherapy in patients with intermediate- or high-risk smoldering multiple myeloma (SMM). Dr Landgren outlines the findings ...

The impact of daratumumab refractoriness on clinical outcomes ...

The real-world safety & efficacy of talquetamab in patients with heavily pretreated R/R myeloma. VJHemOnc – Video Journal of Hematology ...

daratumumab monotherapy in newly diagnosed stage 3B ... - YouTube

II study that investigated daratumumab monotherapy in newly diagnosed patients with stage 3B light chain (AL) amyloidosis. The study's ...

Approaching a myeloma population becoming increasingly resistant ...

... patients with relapsed/refractory multiple myeloma (R/R MM) who have developed resistance to daratumumab. Prof. Morgan explains that daratumumab ...

Daratumumab Plus VRd for Multiple Myeloma | NEJM - YouTube

New multiple myeloma treatments are needed to attain long-term disease control. Adding the monoclonal antibody daratumumab to standard ...